↓ Skip to main content

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Overview of attention for article published in Journal of Venomous Animals and Toxins including Tropical Diseases, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

blogs
1 blog
twitter
3 X users
facebook
1 Facebook page

Readers on

mendeley
98 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview
Published in
Journal of Venomous Animals and Toxins including Tropical Diseases, April 2017
DOI 10.1186/s40409-017-0109-8
Pubmed ID
Authors
Abstract

Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Australia 1 1%
Unknown 97 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 14 14%
Student > Ph. D. Student 10 10%
Student > Master 10 10%
Researcher 10 10%
Student > Doctoral Student 7 7%
Other 9 9%
Unknown 38 39%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 14 14%
Agricultural and Biological Sciences 12 12%
Biochemistry, Genetics and Molecular Biology 7 7%
Neuroscience 5 5%
Chemistry 4 4%
Other 12 12%
Unknown 44 45%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2022.
All research outputs
#4,118,450
of 28,695,121 outputs
Outputs from Journal of Venomous Animals and Toxins including Tropical Diseases
#56
of 521 outputs
Outputs of similar age
#64,197
of 331,588 outputs
Outputs of similar age from Journal of Venomous Animals and Toxins including Tropical Diseases
#3
of 15 outputs
Altmetric has tracked 28,695,121 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 521 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,588 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.